…of significant unmet medical need.” The use of click chemistry to activate cancer drugs at the tumour has been clinically validated. In a Phase I study, click chemistry was used…

…therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs)….

…revolutionise our ability to experiment and accelerate results across engineering biology.” Dr Matt Hayes, Chief Technology Officer at Evonetix, added: “Our technology brings together entirely new approaches to chemistry and…

…Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how Cancer Research Horizons operates within…

The latest sponsored DDW Sitting Down With podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons….

…AVA3996 combines a proprietary proteasome inhibitor (called AVA2727D) with Avacta’s tumour targeting chemistry, creating the potential to reduce the systemic toxicities and thereby make it possible to treat solid tumours…

…Senior Scientist in Discovery Biology at Tango Therapeutics The event’s co-chairs were Zoran Rankovic, Director of CBT Chemistry Centers, and Adrian Gill, Senior Vice President Discovery Chemistry at Revolution Medicines….

Cancer research has always been a team sport. But as cancer science delves ever deeper into chemistry, physics, data science, basic biology, and immunology, all these disciplines need to collaborate…

…Outstanding Achievement in Chemistry in Cancer Research Another award highlight was the AACR Award for Outstanding Achievement in Chemistry in Cancer Research. This award is presented for outstanding, novel, and…

…and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product…